Developer docs
API playgroundTry for free, no card

Search company profiles

35Pharma

Full company profile

uuid0000ux6

Namestring
35Pharma
Legal namestring
35Pharma Inc.
Websiteurl
35pharma.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

35Pharma is a clinical-stage biopharmaceutical company headquartered in Montreal, Canada (with a US office in Boston, Massachusetts) that designs and develops next-generation Activin x GDF ligand traps targeting diseases of high unmet medical need, including pulmonary hypertension, heart failure, and obesity. The company's core platform centers on multi-specific protein therapeutics engineered to selectively neutralize pathological Activin and GDF ligands while sparing BMP-9 and BMP-10, a design intended to overcome the bleeding, telangiectasia, and pericardial effusion safety liabilities that plagued earlier-generation TGF-beta superfamily traps. Lead candidate HS235 is in Phase I/II development for Pulmonary Arterial Hypertension (PAH, Group 1 PH) and Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF, Group 2 PH), with additional programs HS135 (pulmonary hypertension) and HS370 (heart failure/obesity, discovery stage) expanding the pipeline. HS235 is designed for infrequent subcutaneous administration with extended half-life and offers a differentiated dual cardio-pulmonary and metabolic mode of action, including dose-dependent visceral fat reduction with lean mass preservation demonstrated in Phase 1 healthy volunteer trials.

The company operated as a pre-revenue, venture-backed private biotech prior to its acquisition by GSK plc for $950 million in cash, announced February 2026 and completed April 2026. Prior funding came through a Series A led by venBio Partners (2021), a Series B led by Logos Capital (January 2024), and a $53 million Series C led by Frazier Life Sciences (November 2024) with participation from Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors, Columbia Threadneedle, Surveyor Capital, and Marshall Wace. The go-to-market model was a traditional clinical-stage biotech approach focused on building clinical evidence through scientific congress presentations (AHA, ERS, ObesityWeek, CVCT), peer-reviewed publications, and investor conferences (J.P. Morgan Healthcare Conference, TD Cowen, Leerink Partners) to attract a strategic acquirer.

Leadership and scientific founders are alumni of Forbius (acquired by Bristol Myers Squibb in 2020) and include Ilia Tikhomirov (CEO, serial biotech entrepreneur), Maureen O'Connor (CSO, 14 patents and 100+ publications in TGF-beta biology), Walter Blättler (Chairman, scientific founder of ImmunoGen and inventor of Kadcyla), and George Georges (CMO, 25+ years and 45+ clinical trials in pulmonary and critical care medicine). The Board included Guy Braunstein, former Head of Global Clinical Development at Actelion (acquired by Janssen for $30 billion), providing deep pulmonary hypertension drug development expertise. The company was recognized as BIOTECanada's 2025 Promising Biotech Company of the Year and Ilia Tikhomirov was a 2026 Bloom Burton Award finalist, with the award citing the GSK acquisition as the contribution to Canadian innovative healthcare.

Short descriptiontext

35Pharma is a clinical-stage biopharmaceutical company developing next-generation Activin x GDF ligand traps for pulmonary hypertension, heart failure, and obesity, acquired by GSK for $950 million in April 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical drug development, ligand trap therapeutics, pulmonary hypertension treatment, cardiometabolic disease therapy, TGF-beta superfamily biologics
Industry4 codes
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pulmonary Hypertension Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Acquisition/Exit
TypeLicensing Royalties
Description

35Pharma was a clinical-stage private biotech company that was acquired by GSK for $950 million in cash in April 2026. Prior to acquisition, the company had no commercial revenue and was funded through venture capital financing rounds including Series A (venBio), Series B (Logos Capital), and Series C ($53M led by Frazier Life Sciences).

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

35Pharma designs and develops next-generation multi-specific Activin x GDF ligand trap biologics for the treatment of pulmonary hypertension, heart failure, and obesity. The lead candidate HS235 is in Phase I/II clinical development as a potential best-in-class activin signaling inhibitor that selectively neutralizes pathological Activin and GDF ligands while sparing BMP-9 and BMP-10 to reduce bleeding and vascular side effects. The pipeline also includes HS370 (discovery stage) and HS135 (pulmonary hypertension).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Deep and sustained target engagement demonstrated via dose-dependent FSH reductions in postmenopausal females at doses 0.5-2 mg/kg
+2 more records
Product overview1 text field

35Pharma is a clinical-stage biopharmaceutical company developing a pipeline of next-generation Activin x GDF ligand traps for pulmonary hypertension, heart failure, and obesity. The company's core technology platform centers on multi-specific protein therapeutics that selectively neutralize pathological Activin and GDF ligands while sparing beneficial BMP ligands. The lead product HS235 (Phase I/II) addresses Pulmonary Arterial Hypertension and PH-HFpEF, with additional candidates HS370 (discovery, heart failure/obesity) and HS135 (pulmonary hypertension) expanding the portfolio. All candidates leverage the company's ligand trap technology platform enabling tailored multi-specificity and potency for the TGF-beta superfamily signaling pathway.

Product and service3 records
1HS235
CategoryActivin x GDF ligand trap biologic (lead product)
Description

HS235 is 35Pharma's lead multi-specific Activin x GDF decoy trap engineered for exceptional selectivity, potency, and extended half-life. It is undergoing Phase I/II clinical proof-of-concept studies for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF). HS235 is designed to potently block pathological Activins and GDFs while sparing BMP-9 and BMP-10 to reduce bleeding and vascular side effects, and is administered by infrequent subcutaneous injection.

2HS370
CategoryActivin x GDF ligand trap biologic (pipeline product)
Description

HS370 is a next-generation Activin x GDF ligand trap in discovery stage targeting heart failure and obesity, representing an expansion of the company's pipeline of multi-specific traps targeting the Activin and GDF signaling pathway.

3HS135
CategoryActivin inhibitor biologic (pipeline product)
Description

HS135 is a pipeline candidate for pulmonary hypertension, part of 35Pharma's activin inhibitor portfolio for cardiometabolic disease, supported through initial clinical proof-of-concept studies using Series C financing.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

GSK acquired 35Pharma for $950 million in cash in February 2026 (completed April 2026). The acquisition gives GSK full ownership of 35Pharma's pipeline including HS235, a best-in-class activin signaling inhibitor for pulmonary hypertension. GSK is a global biopharma company with expertise in respiratory and inflammatory drivers of disease.

Strategic tierMinorTypeOthersAnnounced on2026-02-25
Description

Served as US legal counsel to 35Pharma for the GSK acquisition transaction.

Strategic tierMinorTypeOthersAnnounced on2026-02-25
Description

Served as Canadian legal counsel to 35Pharma for the GSK acquisition transaction.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Merck acquired Acceleron Pharma and now markets Winrevair (sotatercept), an activin pathway inhibitor approved for PAH. Winrevair is the most direct competitor to 35Pharma's HS235 in the pulmonary hypertension space, targeting the same activin receptor signaling pathway.

2Actelion (Johnson & Johnson Innovative Medicine)
TypeBroad incumbent
Description

Actelion (acquired by J&J for $30B) is the historical PAH market leader, having commercialized Tracleer, Opsumit, and Uptravi. 35Pharma's board includes Actelion's former Head of Global Clinical Development, and the company competes with J&J/Actelion in the broader PH market.

TypeBroad incumbent
Description

United Therapeutics markets Tyvaso, Remodulin, and Orenitram for PAH and PH-ILD. It is an established commercial player in pulmonary hypertension with a broad portfolio of prostacyclin-based therapies, making it a direct commercial competitor for any activin inhibitor entering the PH market.

TypeOthers
Description

Forbius was 35Pharma's predecessor company, also founded by Ilia Tikhomirov and Maureen O'Connor, focused on TGF-beta biologics. Forbius was acquired by Bristol-Myers Squibb in 2020, and most of 35Pharma's senior team came from Forbius, making it the closest precedent for the team's track record.

TypeEmerging player
Description

Keros Therapeutics develops engineered proteins targeting the TGF-beta superfamily, including activin receptor ligands, for hematological and musculoskeletal diseases. It is the most direct emerging competitor in the activin biology space, pursuing a related but distinct set of indications from 35Pharma.

TypeEmerging player
Description

Disc Medicine is a clinical-stage biopharmaceutical company focused on hematology and rare diseases, with a pipeline modulating TGF-beta superfamily signaling. It represents an adjacent competitor in the same protein engineering biology space as 35Pharma.

TypeEmerging player
Description

Pliant Therapeutics develops therapies targeting integrin biology and tissue fibrosis, with connections to TGF-beta signaling. It is an emerging clinical-stage company in related tissue-remodeling and fibrosis indications that overlap with 35Pharma's HFpEF and PH programs.

8Bristol-Myers Squibb
TypeOthers
Description

BMS acquired Forbius (35Pharma's predecessor) in 2020 and now houses AVID200, a TGF-beta-1/3 selective trap. BMS is a relevant comparator as both a strategic acquirer in the space and a potential competitor with related activin/TGF-beta assets from the Forbius acquisition.

TypeOthers
Description

GSK acquired 35Pharma in 2026 for $950M. While now the parent company, GSK is also a relevant comparator in respiratory and cardiovascular biopharma, with potential overlapping pipeline programs that could compete with or complement HS235's development.

TypeRegional player
Description

Idorsia is a Swiss biopharmaceutical company focused on cardiovascular and central nervous system diseases. Board director Guy Braunstein previously served as EVP and CMO at Idorsia, and the company is a relevant European peer in the cardiovascular development space that 35Pharma targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

35Pharma

Pulmonary Hypertension Biologics35pharma.com

35Pharma is a clinical-stage biopharmaceutical company developing next-generation Activin x GDF ligand traps for pulmonary hypertension, heart failure, and obesity, acquired by GSK for $950 million in April 2026.

What 35Pharma does

35Pharma is a clinical-stage biopharmaceutical company headquartered in Montreal, Canada (with a US office in Boston, Massachusetts) that designs and develops next-generation Activin x GDF ligand traps targeting diseases of high unmet medical need, including pulmonary hypertension, heart failure, and obesity. The company's core platform centers on multi-specific protein therapeutics engineered to selectively neutralize pathological Activin and GDF ligands while sparing BMP-9 and BMP-10, a design intended to overcome the bleeding, telangiectasia, and pericardial effusion safety liabilities that plagued earlier-generation TGF-beta superfamily traps. Lead candidate HS235 is in Phase I/II development for Pulmonary Arterial Hypertension (PAH, Group 1 PH) and Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF, Group 2 PH), with additional programs HS135 (pulmonary hypertension) and HS370 (heart failure/obesity, discovery stage) expanding the pipeline. HS235 is designed for infrequent subcutaneous administration with extended half-life and offers a differentiated dual cardio-pulmonary and metabolic mode of action, including dose-dependent visceral fat reduction with lean mass preservation demonstrated in Phase 1 healthy volunteer trials.

The company operated as a pre-revenue, venture-backed private biotech prior to its acquisition by GSK plc for $950 million in cash, announced February 2026 and completed April 2026. Prior funding came through a Series A led by venBio Partners (2021), a Series B led by Logos Capital (January 2024), and a $53 million Series C led by Frazier Life Sciences (November 2024) with participation from Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors, Columbia Threadneedle, Surveyor Capital, and Marshall Wace. The go-to-market model was a traditional clinical-stage biotech approach focused on building clinical evidence through scientific congress presentations (AHA, ERS, ObesityWeek, CVCT), peer-reviewed publications, and investor conferences (J.P. Morgan Healthcare Conference, TD Cowen, Leerink Partners) to attract a strategic acquirer.

Leadership and scientific founders are alumni of Forbius (acquired by Bristol Myers Squibb in 2020) and include Ilia Tikhomirov (CEO, serial biotech entrepreneur), Maureen O'Connor (CSO, 14 patents and 100+ publications in TGF-beta biology), Walter Blättler (Chairman, scientific founder of ImmunoGen and inventor of Kadcyla), and George Georges (CMO, 25+ years and 45+ clinical trials in pulmonary and critical care medicine). The Board included Guy Braunstein, former Head of Global Clinical Development at Actelion (acquired by Janssen for $30 billion), providing deep pulmonary hypertension drug development expertise. The company was recognized as BIOTECanada's 2025 Promising Biotech Company of the Year and Ilia Tikhomirov was a 2026 Bloom Burton Award finalist, with the award citing the GSK acquisition as the contribution to Canadian innovative healthcare.

35Pharma firmographics

Firmographics
Name
35Pharma
Legal name
35Pharma Inc.
Website
https://35pharma.com
Company type
Private
Founded year
2014
Operating status
Acquired
Headcount range
11–50 employees
Short description
35Pharma is a clinical-stage biopharmaceutical company developing next-generation Activin x GDF ligand traps for pulmonary hypertension, heart failure, and obesity, acquired by GSK for $950 million in April 2026.
Ownership category
akta.pro rank

35Pharma industry classification

Industry
Product category
Pulmonary Hypertension Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • Biopharmaceutical drug development
  • Ligand trap therapeutics
  • Pulmonary hypertension treatment
  • Cardiometabolic disease therapy
  • TGF-beta superfamily biologics

Where 35Pharma is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

35Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Acquisition/Exit: 35Pharma was a clinical-stage private biotech company that was acquired by GSK for $950 million in cash in April 2026. Prior to acquisition, the company had no commercial revenue and was funded through venture capital financing rounds including Series A (venBio), Series B (Logos Capital), and Series C ($53M led by Frazier Life Sciences).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

35Pharma product offering

Product offering

Core offering

35Pharma designs and develops next-generation multi-specific Activin x GDF ligand trap biologics for the treatment of pulmonary hypertension, heart failure, and obesity. The lead candidate HS235 is in Phase I/II clinical development as a potential best-in-class activin signaling inhibitor that selectively neutralizes pathological Activin and GDF ligands while sparing BMP-9 and BMP-10 to reduce bleeding and vascular side effects. The pipeline also includes HS370 (discovery stage) and HS135 (pulmonary hypertension).

Product overview

35Pharma is a clinical-stage biopharmaceutical company developing a pipeline of next-generation Activin x GDF ligand traps for pulmonary hypertension, heart failure, and obesity. The company's core technology platform centers on multi-specific protein therapeutics that selectively neutralize pathological Activin and GDF ligands while sparing beneficial BMP ligands. The lead product HS235 (Phase I/II) addresses Pulmonary Arterial Hypertension and PH-HFpEF, with additional candidates HS370 (discovery, heart failure/obesity) and HS135 (pulmonary hypertension) expanding the portfolio. All candidates leverage the company's ligand trap technology platform enabling tailored multi-specificity and potency for the TGF-beta superfamily signaling pathway.

Differentiator

Problem solved

Functional benefit

Products and services

  • HS235 HS235 is 35Pharma's lead multi-specific Activin x GDF decoy trap engineered for exceptional selectivity, potency, and extended half-life. It is undergoing Phase I/II clinical proof-of-concept studies for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF). HS235 is designed to potently block pathological Activins and GDFs while sparing BMP-9 and BMP-10 to reduce bleeding and vascular side effects, and is administered by infrequent subcutaneous injection.
  • HS370 HS370 is a next-generation Activin x GDF ligand trap in discovery stage targeting heart failure and obesity, representing an expansion of the company's pipeline of multi-specific traps targeting the Activin and GDF signaling pathway.
  • HS135 HS135 is a pipeline candidate for pulmonary hypertension, part of 35Pharma's activin inhibitor portfolio for cardiometabolic disease, supported through initial clinical proof-of-concept studies using Series C financing.

Quantifiable outcome

  • Deep and sustained target engagement demonstrated via dose-dependent FSH reductions in postmenopausal females at doses 0.5-2 mg/kg
  • +2 more outcomes

Companies that use 35Pharma

Customer profile

Segments3 records

Ideal customer profiles2 records

35Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

35Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • GSKcoreStrategic or Co-development Partner · 25 February 2026GSK acquired 35Pharma for $950 million in cash in February 2026 (completed April 2026). The acquisition gives GSK full ownership of 35Pharma's pipeline including HS235, a best-in-class activin signaling inhibitor for pulmonary hypertension. GSK is a global biopharma company with expertise in respiratory and inflammatory drivers of disease.
  • Cooley LLPminorOthers · 25 February 2026Served as US legal counsel to 35Pharma for the GSK acquisition transaction.
  • Stikeman Elliott LLPminorOthers · 25 February 2026Served as Canadian legal counsel to 35Pharma for the GSK acquisition transaction.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

35Pharma competitors and assessment

Company assessment

Direct peers

  • Merck & Co. (Acceleron): Merck acquired Acceleron Pharma and now markets Winrevair (sotatercept), an activin pathway inhibitor approved for PAH. Winrevair is the most direct competitor to 35Pharma's HS235 in the pulmonary hypertension space, targeting the same activin receptor signaling pathway.

Broad incumbents

  • Actelion (Johnson & Johnson Innovative Medicine): Actelion (acquired by J&J for $30B) is the historical PAH market leader, having commercialized Tracleer, Opsumit, and Uptravi. 35Pharma's board includes Actelion's former Head of Global Clinical Development, and the company competes with J&J/Actelion in the broader PH market.
  • United Therapeutics: United Therapeutics markets Tyvaso, Remodulin, and Orenitram for PAH and PH-ILD. It is an established commercial player in pulmonary hypertension with a broad portfolio of prostacyclin-based therapies, making it a direct commercial competitor for any activin inhibitor entering the PH market.

Others

  • Forbius: Forbius was 35Pharma's predecessor company, also founded by Ilia Tikhomirov and Maureen O'Connor, focused on TGF-beta biologics. Forbius was acquired by Bristol-Myers Squibb in 2020, and most of 35Pharma's senior team came from Forbius, making it the closest precedent for the team's track record.
  • Bristol-Myers Squibb: BMS acquired Forbius (35Pharma's predecessor) in 2020 and now houses AVID200, a TGF-beta-1/3 selective trap. BMS is a relevant comparator as both a strategic acquirer in the space and a potential competitor with related activin/TGF-beta assets from the Forbius acquisition.
  • GSK: GSK acquired 35Pharma in 2026 for $950M. While now the parent company, GSK is also a relevant comparator in respiratory and cardiovascular biopharma, with potential overlapping pipeline programs that could compete with or complement HS235's development.

Emerging players

  • Keros Therapeutics: Keros Therapeutics develops engineered proteins targeting the TGF-beta superfamily, including activin receptor ligands, for hematological and musculoskeletal diseases. It is the most direct emerging competitor in the activin biology space, pursuing a related but distinct set of indications from 35Pharma.
  • Disc Medicine: Disc Medicine is a clinical-stage biopharmaceutical company focused on hematology and rare diseases, with a pipeline modulating TGF-beta superfamily signaling. It represents an adjacent competitor in the same protein engineering biology space as 35Pharma.
  • Pliant Therapeutics: Pliant Therapeutics develops therapies targeting integrin biology and tissue fibrosis, with connections to TGF-beta signaling. It is an emerging clinical-stage company in related tissue-remodeling and fibrosis indications that overlap with 35Pharma's HFpEF and PH programs.

Regional players

  • Idorsia Ltd: Idorsia is a Swiss biopharmaceutical company focused on cardiovascular and central nervous system diseases. Board director Guy Braunstein previously served as EVP and CMO at Idorsia, and the company is a relevant European peer in the cardiovascular development space that 35Pharma targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

35Pharma social profiles

Digital presence

35Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

35Pharma leadership team

Management profile

Number of profiles

Profiles14 records

35Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

35Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 35Pharma

What does 35Pharma do?

35Pharma designs and develops next-generation multi-specific Activin x GDF ligand trap biologics for the treatment of pulmonary hypertension, heart failure, and obesity. The lead candidate HS235 is in Phase I/II clinical development as a potential best-in-class activin signaling inhibitor that selectively neutralizes pathological Activin and GDF ligands while sparing BMP-9 and BMP-10 to reduce bleeding and vascular side effects. The pipeline also includes HS370 (discovery stage) and HS135 (pulmonary hypertension).

Is 35Pharma a public or private company?

35Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was 35Pharma founded?

35Pharma was founded in 2014. It employs 11 to 50 people.

Where is 35Pharma based?

35Pharma is headquartered in Montreal, Canada, in the North America region.

How does 35Pharma make money?

One revenue line is on record: acquisition/Exit.

Who are 35Pharma's main competitors?

Merck & Co. (Acceleron) is listed as a direct peer. Broad incumbents are Actelion (Johnson & Johnson Innovative Medicine) and United Therapeutics. Others are Forbius, Bristol-Myers Squibb and GSK. Emerging players are Keros Therapeutics, Disc Medicine and Pliant Therapeutics. Idorsia Ltd is listed as a regional player.

Does 35Pharma have an API?

No public API is recorded for 35Pharma.

What industry is 35Pharma in?

35Pharma's product category is Pulmonary Hypertension Biologics. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswireCPE Media & Data Company: Lowest Level of International Venture Capital Funding - Canadian VC H1 2026Canadian venture capital investment fell 12% to $2.481 billion in H1 2026, down from $3.215 billion in H1 2025. International investor participation hit its lowest level since 2020, with U.S. investors' share rising to 56%. Canada has not had a venture-backed IPO since 2021.European BiotechnologyGSK announces plan to axe UK Stevenage R&D hub, moving to CambridgeGSK announced plans to close its UK R&D headquarters in Stevenage and move operations to a new 300,000-square-foot site in Cambridge, with a phased employee move by 2029. The company also unveiled a three-year cost-cutting programme targeting £1.9 billion in annual savings by 2029, and plans to invest £400 million over three years.DealformaCardiovascular R&D Partnerships, M&A and Venture FundingCardiovascular R&D activity rebounded sharply in Q1 2026, with 6 partnerships generating $3.1 billion in total value and $110 million in upfront payments, compared with just 1 deal in Q4 2025. M&A accelerated significantly, with 7 acquisitions valued at $11.2 billion including Danaher's $9.9 billion acquisition of Masimo, GSK's $950 million purchase of 35Pharma, and Sino Biopharm's acquisition of Hygieia Pharmaceuticals for approximately $172 million. Venture funding moderated to $789 million across 17 rounds, with notable raises by Corxel Pharmaceuticals ($287 million), Corsera Health ($80 million), and Inquis Medical ($75 million).Pharmaceutical TechnologyGSK spends $1bn on rights to SiranBio’s metabolic oligonucleotide - Pharmaceutical TechnologyGSK acquired global rights to SiranBio's metabolic oligonucleotide SA030 for up to $1bn, with an upfront payment and milestones. The ALK7-targeting therapy aims to reduce abdominal fat while preserving muscle mass, offering an alternative to GLP-1RAs. GSK is also investing in other metabolic assets like 35Pharma.YahooGSK (GSK) Completes $950M Acquisition to Expand Drug PipelineGSK plc completed the acquisition of 35Pharma Inc., a private Canadian clinical-stage biopharmaceutical firm, for $950 million, gaining full control of its pipeline including HS235, a drug candidate for pulmonary arterial hypertension treatment. Early clinical trials showed HS235 demonstrated metabolic advantages including fat-selective weight reduction and improved insulin sensitivity. Separately, GSK announced positive preliminary data for its cancer medicine Mo-rez, with 62% of platinum-resistant ovarian cancer patients and 67% of endometrial cancer patients achieving substantial tumor reduction.TradingViewThree Finalists Announced for the 2026 Bloom Burton AwardBloom Burton & Co. announced the four finalists for the 2026 Bloom Burton Award, which honors an individual who made the greatest contribution to Canada's innovative healthcare industry, with finalists being Ian Mortimer of Xenon Pharmaceuticals, Graham Rosenberg and Nate Tchaplia of Dentalcorp, and Ilia Tikhomirov, former CEO of 35Pharma. The finalists represent companies that achieved significant milestones, including Xenon's US$747.5 million follow-on financing (largest by an R&D-stage biopharma in Canadian history) and positive phase 3 clinical trial results, Dentalcorp's $3.3 billion acquisition by GTCR, and 35Pharma's acquisition by GSK for US$950 million. The award winner will be announced at the gala on September 24, 2026, at The Ritz-Carlton in Toronto.NewsfileThree Finalists Announced for the 2026 Bloom Burton AwardBloom Burton announced three finalists for the 2026 Bloom Burton Award: Ian Mortimer of Xenon Pharmaceuticals, Graham Rosenberg and Nate Tchaplia of Dentalcorp, and Ilia Tikhomirov of 35Pharma. The award honors contributions to Canada's healthcare industry, with finalists selected by an independent panel. The winner will be announced at the gala on September 24, 2026.BioSpaceThree Finalists Announced for the 2026 Bloom Burton AwardBloom Burton announced three finalists for the 2026 Bloom Burton Award: Ian Mortimer of Xenon Pharmaceuticals, Graham Rosenberg and Nate Tchaplia of Dentalcorp, and Ilia Tikhomirov of 35Pharma. The finalists are recognized for significant contributions to Canada's healthcare industry, with the winner to be announced at the gala on September 24, 2026.FierceBiotechWhich blockbuster is GSK gunning for next? CEO Miels is looking to oncologyGSK CEO Luke Miels outlined the company's dealmaking strategy focused on acquiring targets that can improve upon existing blockbuster drugs, with oncology identified as a particularly promising area. Recent deals include the $2.2 billion acquisition of Rapt Therapeutics and the $950 million purchase of Canadian biotech 35Pharma, both aimed at addressing underserved or suboptimal treatments. Miels declined to specify which additional blockbusters GSK is pursuing but indicated there are multiple areas with established product portfolios that could be improved.